Cerevisterol
(Synonyms: 啤酒甾醇) 目录号 : GC45716
A fungal metabolite
Cas No.:516-37-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >70.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cerevisterol is an ergosterol fungal metabolite originally isolated from S. cerevisiae that has diverse biological activities, including antimicrobial, anti-inflammatory, and anticancer properties.1 It is active against the bacteria S. typhi, S. aureus, and E. faecalis (MICs = 25, 25, and 50 μg/ml, respectively) and the fungus A. niger (MIC = 25 μg/ml), but has no effect on the bacteria E. coli, P. aeruginosa, S. pyogenes, K. pneumoniae, and B. subtilis, or the fungi C. albicans, A. flavus, and A. tamarii when used at concentrations up to 400 μg/ml.2 Cerevisterol (2-20 μM) inhibits LPS-induced increases in the levels of nitric oxide (NO), TNF-α, IL-6, IL-10, and prostaglandin E2 in RAW 264.7 cells.3 It inhibits proliferation of MCF-7, MDA-MB-231, and Caco-2 cancer cells (EC50s = 64.5, 52.4, and 37.6 μM, respectively), but not PC3, PANC-1, or A549 cells (IC50 = >100 μM for all).4,5
|1. Bills, C.E., and Honeywell, E.M. Antiricketic substances: VIII. Studies on highly purified ergosterol and its esters. J. Biol. Chem. 80, 15-23 (1928).|2. Appiah, T., Agyare, C., Luo, Y., et al. Antimicrobial and resistance modifying activities of cerevisterol isolated from Trametes species. Curr. Bioact. Compd. 14, (2018).|3. Liu, Y.-W., Mei, H.-C., Su, Y.-W., et al. Inhibitory effects of Pleurotus tuber-regium mycelia and bioactive constituents on LPS-treated RAW 264.7 cells. J. Funct. Foods 7, 662-670 (2014).|4. Wang, H., Liu, T., and Xin, Z. A new glucitol from an endophytic fungus Fusarium equiseti Salicorn 8. Eur. Food Res. Technol. 239(3), 365-376 (2014).|5. Wang, Q.-X., Li, S.-F., Zhao, F., et al. Chemical constituents from endophytic fungus Fusarium oxysporum. Fitoterapia 82(5), 777-781 (2011).
| Cas No. | 516-37-0 | SDF | |
| 别名 | 啤酒甾醇 | ||
| Canonical SMILES | C[C@H](/C=C/[C@H](C)C(C)C)[C@@]1([H])CC[C@@]2([H])C3=C[C@@H](O)[C@@]4(O)C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@@]21C | ||
| 分子式 | C28H46O3 | 分子量 | 430.7 |
| 溶解度 | DMSO: soluble,Ethanol: soluble,Methanol: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3218 mL | 11.609 mL | 23.218 mL |
| 5 mM | 0.4644 mL | 2.3218 mL | 4.6436 mL |
| 10 mM | 0.2322 mL | 1.1609 mL | 2.3218 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Cerevisterol Alleviates Inflammation via Suppression of MAPK/NF-κB/AP-1 and Activation of the Nrf2/HO-1 Signaling Cascade
Biomolecules 2020 Jan 29;10(2):199.PMID:32013140DOI:10.3390/biom10020199.
As part of our continuous effort to find potential anti-inflammatory agents from endophytic fungi, a Fusariumsolani strain, isolated from the plant Aponogetonundulatus Roxb., was investigated. Cerevisterol (CRVS) was identified from endophytic fungi, a Fusariumsolani strain, and moreover exhibited anti-inflammatory activity. However, the underlying mode of action remains poorly understood. The aim of this study is to reveal the potential mechanisms of CRVS against inflammation on a molecular level in LPS-activated RAW 264.7 peritoneal macrophage cells. CRVS was isolated from F.solani and characterized based on spectral data analysis. The MTT assay was performed to measure cell viability in CRVS-treated macrophages. Anti-inflammatory activity was assessed by measurement of nitric oxide (NO) and prostaglandin E2 (PGE2) levels, as well as the production of various cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and -6 (IL-6) in LPS-stimulated macrophages. RT-PCR and immunoblotting analyses were done to examine the expression of various inflammatory response genes. A reporter gene assay was conducted to measure the level of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activator protein-1 (AP-1) transactivation. CRVS suppresses the LPS-induced production of NO and PGE2, which is a plausible mechanism for this effect is by reducing the expression of iNOS and COX-2. CRVS also decreases the expression of pro-inflammatory cytokines, such as TNF-α, IL-6, and IL-1β. CRVS halted the nuclear translocation of NF-κB by blocking the phosphorylation of inhibitory protein κBα (IκBα) and suppressing NF-κB transactivation. The mitogen-activated protein kinases (MAPK) signaling pathways are also suppressed. CRVS treatment also inhibited the transactivation of AP-1 and the phosphorylation of c-Fos. Furthermore, CRVS could induce the nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) by down-regulating Kelch-like ECH-associated protein 1 (Keap-1) and up-regulating hemeoxygenases-1 (HO-1) expression. The results suggest that CRVS acts as a natural agent for treating inflammatory diseases by targeting an MAPK, NF-κB, AP-1, and Nrf2-mediated HO-1 signaling cascade.
New insights into antimicrobial and antibiofilm effects of edible mushrooms
Food Res Int 2022 Dec;162(Pt A):111982.PMID:36461225DOI:10.1016/j.foodres.2022.111982.
The antimicrobial resistance (AMR) has opened a new market for functional foods with antibacterial activities. More than ever before, people are interested in the natural foods that offer a pathogen fighting benefits due to their obvious advantages over management of diseases. Consumers who are health aware are continually using functional foods in their dietary regimens both for their nutritious, associated health benefits values and convenience. Examples include plant-based essential oils, garlic, and mushrooms. Many studies were conducted on mushrooms crude extracts as functional food with antimicrobial properties, yet the bioactive compounds isolated are few or even rare. Because antimicrobial resistance and biofilm formation are exacerbating the severity of infectious diseases worldwide, this review summarized the antimicrobial molecules compared to the number of extracts as well as the biofilm acting compounds and extracts from edible mushrooms in the last seven years to facilitate drawing the roadmap of anti-infectious agent's discovery from functional foods in the future. 156 compounds and more than 100 edible mushroom extracts with antibacterial, antifungal or biofilm inhibiting activities through the period from 2015 to 2022 were reviewed. Pubmed, Web of Science, and Scopus were thoroughly searched with relevant search words, and data reviewed indicated ninety active compounds against Gram (-ve), hundred and twenty active compounds against Gram (+ve), sixty-eight active compounds against fungi. The biofilm inhibition was revealed by nineteen compounds. Effective combinations active in biofilm inhibition were represented by quinic acid with uridine/inosine or adenine/oxalic mixtures. Activities against multi-resistant strains, represented by ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), MRSA (Methicillin Resistant Staphylococcus aureus), VRSA (Vancomycin Resistant Staphylococcus aureus) and multi-resistant tuberculosis were shown by 39 compounds and extracts. Terpenoid compounds revealed the most potent antimicrobial action; for instance, cyathanes, Cerevisterol, psathyrins and grifolaone. Because variation in cultural media is accompanied by a different response in fungal growth and mass yield as well as the variation of compounds of interest from one strain to another, the methods of isolation, cultures and media used are highlighted together with structure activity relationships when available.
Triterpenes from the Mushroom Hypholoma lateritium: Isolation, Structure Determination and Investigation in Bdelloid Rotifer Assays
Molecules 2019 Jan 15;24(2):301.PMID:30650625DOI:10.3390/molecules24020301.
Twelve compounds (1⁻12) were isolated from the methanol extract of brick cap mushroom (Hypholoma lateritium (Schaeff.) P. Kumm.). The structures of the compounds were elucidated using extensive spectroscopic analyses, including NMR and MS measurements. Lanosta-7,9(11)-diene-12β,21α-epoxy-2α,3β,24β,25-tetraol (1) and 8-hydroxy-13-oxo-9E,11E-octa-decadienoic acid (2) were identified as new natural products, together with ten known compounds, from which 3β-hydroxyergosta-7,22-diene (4), demethylincisterol A2 (5), Cerevisterol (6), 3β-O-glucopyranosyl-5,8-epidioxyergosta-6,22-diene (7), fasciculol E (9), and uridine (12) were identified in this species for the first time. The isolated triterpenes (1, 3⁻11) were investigated for their toxicity in vivo using bdelloid rotifer assays. Most of the examined steroids in general showed low toxicity, although the effects of the compounds varied in a wider range from the non-toxic lanosta-7,9(11)-diene-12β,21α-epoxy-2α,3β,24β,25-tetraol (1) to the significantly toxic Cerevisterol (6), with substantial dependence in some cases on the presence of nutrient in the experimental environment.
Bioactive metabolites from the mycelia of the basidiomycete Hericium erinaceum
Nat Prod Res 2014;28(16):1288-92.PMID:24635196DOI:10.1080/14786419.2014.898145.
Seven known compounds, three diketopiperazine alkaloids, 12β-hydroxyverruculogen TR-2 (1), fumitremorgin C (2) and methylthiogliotoxin (5), two hetero-spirocyclic γ-lactam alkaloids, pseurotin A (3) and FD-838 (4), and Cerevisterol (6) and herierin IV (7), were isolated from the mycelia of the basidiomycete Hericium erinaceum and identified by spectroscopic analyses. The antioxidant and antifungal activities of compounds 1-6 were evaluated. The results indicated that compounds 1, 3 and 6 exhibited potential antioxidant activity against DPPH (2, 2-diphenyl-1-picrylhydrazyl) radical with their IC50 data of ca. 12 μM, compared with positive control tertiary butylhydroquinone. In addition, compound 4 significantly inhibited the growth of two plant fungal pathogens Botrytis cinerea and Glomerella cingulata with an minimum inhibitory concentration of 6.25 μM for each, similar to that of the positive fungicide, carbendazim. Compounds 1-5 were isolated from the genus Hericium for the first time.
Antimicrobial anthraquinones from cultures of the ant pathogenic fungus Cordyceps morakotii BCC 56811
J Antibiot (Tokyo) 2019 Mar;72(3):141-147.PMID:30622295DOI:10.1038/s41429-018-0135-y.
Five new anthraquinones, morakotins A-E (1-5), together with seven known compounds, lunatin (6), rheoemodin (7), YM187781 (8), bislunatin (9), 6-(1-hydroxypentyl)-4-methoxypyran-2-one, 9,11-dehydoergrosterol peroxide, and Cerevisterol, were isolated from the insect pathogenic fungus Cordyceps morakotii BCC 56811. The morakotin structures were elucidated from NMR spectroscopic and mass spectrometric data. The absolute configurations of bianthraquinone compounds, morakotins C-E (3-5), were determined by application of the exciton chirality method. Compounds 3, 7, 8, and 9 showed weak to moderate antimycobacterial and antifungal activities. Compounds 4 and 8 exhibited antibacterial activity against both Bacillus cereus and Staphylococcus aureus (MIC 3.13-25 µg ml-1), whereas compounds 3 and 9 were active against B. cereus (MIC 12.5 and 3.13 µg ml-1, respectively), and compound 7 was active against Acinetobacter baumannii (MIC 12.5 µg ml-1).